For Immediate Release
Chicago, IL – April 24, 2012 – Zacks Equity Research highlights
UnitedHealth Group ( UNH) as the Bull of the Day
and Citi Trends, Inc. ( CTRN) as the Bear of the
Day. In addition, Zacks Equity Research provides analysis on
AstraZeneca plc ( AZN), Ardea Biosciences,
Inc. ( RDEA) and Takeda Pharmaceutical (
TKPYY).
Full analysis of all these stocks is available at
http://at.zacks.com/?id=2678.
Here is a synopsis of all five stocks:
Bull of the Day:
UnitedHealth Group's ( UNH) first quarter
earnings came in significantly ahead of the Zacks Consensus
Estimates on the back of strong revenue growth at UnitedHealthcare
as well as Optum businesses and strong enrollment growth. We are
bullish about the company's long-term growth prospects.
UnitedHealth has strengthened its key capabilities to respond to
the emerging growth opportunities. These initiatives have been
taken to expand its Medicaid and Medicare business, growing the
health service business and expanding international operations.
Though certain headwinds remain, we believe the company will beat
the odds given its diversified business model with leading market
share positions in the Commercial, Medicare, and Medicaid
markets.
Our six-month target price of $70.00 equates to about 14.1x our
earnings estimate for 2012. We view the $0.65 per common share
annual dividend as secure, implying an expected return of about 20%
over that period. This is consistent with our Outperform
recommendation on the shares.
Bear of the Day:
Citi Trends, Inc.'s ( CTRN) falling comparable
store sales, coupled with rising cost of goods sold and operating
expenses, battered fourth-quarter 2011 results. The company
incurred a quarterly loss of $0.18 per share, falling drastically
from the year-ago quarter earnings of $0.64 per share. The results,
however, bettered the Zacks Consensus Estimate of a loss of $0.20
per share.
Further, due to uncertainty hovering around sales, given the
global economic unrest, the company decided not to provide any
guidelines unless it finds any near-term catalysts to drive sales.
Intense competition from other retailers, seasonal nature of
business and risks associated with sourcing merchandise from
developing countries may further undermine the company's future
growth prospects.
Currently, we are maintaining a long-term Underperform
recommendation on the stock. Our target price of $10.00 is based on
P/CF (price-to-cash flow) multiple of 8.27x.
Latest Posts on the Zacks Analyst Blog:
AstraZeneca to Buy Ardea
Biosciences
AstraZeneca plc ( AZN) announced that it has
entered into an agreement to acquire Ardea Biosciences,
Inc. ( RDEA) for a consolidated cash value of
approximately $1.26 billion or $32 per share. Both AstraZeneca and
Ardea’s boards have unanimously supported the deal. The deal is
expected to close in second or third quarter of 2012, subject to
certain regulatory conditions, which includes approval by Ardea’s
shareholders.
Ardea, headquartered in San Diego, CA, is a biotech company. The
company primarily develops small-molecule therapeutics for treating
serious diseases such as gout and cancer. Ardea‘s lead candidate is
lesinurad for the chronic treatment of gout, with US and EU
regulatory filings planned for the first half of 2014. The pipeline
also includes oncology candidate, BAY 86-9766, and gout candidate,
RDEA3170.
On approval, the gout candidates will target a highly lucrative
market. We note that the incidence and severity of gout is
increasing in the US. The market has a huge unmet need with
Takeda Pharmaceutical’s ( TKPYY) Uloric
(febuxostat) and allopurinol being two widely-prescribed therapies
(xanthine oxidase inhibitors) for the treatment of gout patients.
The inhibitors reduce the production of uric acid in the body.
However, the effectiveness of xanthine oxidase inhibitors is
limited since only approximately 10% of patients affected by gout
are over-excretors of uric acid. Many gout patients fail to respond
favorably to these therapies. This should provide lesinurad, which
is being evaluated both as add-on and monotherapy, and RDEA3170 the
opportunity to capture the gout market share.
Though the source of funds for the Ardea deal were not
disclosed, it is possible that the cash balance of $7.6 billion at
the end of December 31, 2011, enabled the company to fund the
acquisition. Apart from its cash balance, AstraZeneca has committed
bank facilities of $3.6 billion at its disposal.
Neutral on AstraZeneca
We are encouraged by the company’s focus on the high-potential
emerging markets and are pleased with the company’s effort to drive
the bottom line through cost-cutting initiatives and share
buybacks.
However, we remain concerned about the generic competition faced
by its key products. In 2011, the company lost revenues worth
almost $2 billion to generic competition. The weak late-stage
pipeline coupled with the slow Brilinta uptake also bothers us. We
currently have a Neutral recommendation on AstraZeneca. The stock
carries a Zacks #3 Rank (Hold rating) in the short run.
Get the full analysis of all these stocks by going to
http://at.zacks.com/?id=2649.
About the Bull and Bear of the Day
Every day, the analysts at Zacks Equity Research select two
stocks that are likely to outperform (Bull) or underperform (Bear)
the markets over the next 3-6 months.
About the Analyst Blog
Updated throughout every trading day, the Analyst Blog provides
analysis from Zacks Equity Research about the latest news and
events impacting stocks and the financial markets.
About Zacks Equity Research
Zacks Equity Research provides the best of quantitative and
qualitative analysis to help investors know what stocks to buy and
which to sell for the long-term.
Continuous analyst coverage is provided for a universe of 1,150
publicly traded stocks. Our analysts are organized by industry
which gives them keen insights to developments that affect company
profits and stock performance. Recommendations and target prices
are six-month time horizons.
Zacks "Profit from the Pros" e-mail newsletter provides
highlights of the latest analysis from Zacks Equity Research.
Subscribe to this free newsletter today by visiting
http://at.zacks.com/?id=7158.
About Zacks
Zacks.com is a property of Zacks Investment Research, Inc.,
which was formed in 1978 by Leonard Zacks. As a PhD from MIT Len
knew he could find patterns in stock market data that would lead to
superior investment results. Amongst his many accomplishments was
the formation of his proprietary stock picking system; the Zacks
Rank, which continues to outperform the market by nearly a 3 to 1
margin. The best way to unlock the profitable stock recommendations
and market insights of Zacks Investment
Research is through our free daily email newsletter; Profit from
the Pros. In short, it's your steady flow of Profitable ideas
GUARANTEED to be worth your time! Register for your free
subscription to Profit from the Pros at
http://at.zacks.com/?id=4582.
Visit http://www.zacks.com/performance for information about the
performance numbers displayed in this press release.
Follow us on Twitter: http://twitter.com/zacksresearch
Join us on Facebook:
http://www.facebook.com/home.php#/pages/Zacks-Investment-Research/57553657748?ref=ts
Disclaimer: Past performance does not guarantee future results.
Investors should always research companies and securities before
making any investments. Nothing herein should be construed as an
offer or solicitation to buy or sell any security.
Media Contact
Zacks Investment Research
800-767-3771 ext. 9339
support@zacks.com
http://www.zacks.com
ASTRAZENECA PLC (AZN): Free Stock Analysis Report
CITI TRENDS INC (CTRN): Free Stock Analysis Report
ARDEA BIOSCIENC (RDEA): Free Stock Analysis Report
UNITEDHEALTH GP (UNH): Free Stock Analysis Report
To read this article on Zacks.com click here.
Grafico Azioni Ardea Biosciences, Inc. (MM) (NASDAQ:RDEA)
Storico
Da Mag 2024 a Giu 2024
Grafico Azioni Ardea Biosciences, Inc. (MM) (NASDAQ:RDEA)
Storico
Da Giu 2023 a Giu 2024